Exclusive Summary

• **Best-in-Class Potential with Superior Head-to-Head Data**: Demonstrated faster median time to viral clearance (8.4 days) compared to Pfizer's Paxlovid (9.5 days) with only half the API dosage (300mg vs 600mg), suggesting a superior safety and compliance profile.
• **Robust Efficacy Against Emerging Variants**: Shows 7-10 fold better IC50 values in vitro compared to competitors and stands as the only oral treatment claiming positive clinical efficacy against the Omicron XBB variant.
• **Global Validation via Oxford University**: Currently participating in the Oxford-led PLATCOV multi-center Phase II trial, conducting head-to-head comparisons against Paxlovid and Ensitrelvir, providing high-standard evidence for global markets.
• **Competitive Pharmacoeconomics**: Launched at ~¥498 RMB (vs ~¥1800 for Paxlovid), offering a highly accessible solution for price-sensitive markets in Southeast Asia and Belt & Road countries.
• **LCM and Multi-Indication Potential**: Offers additional licensing value through pipeline expansion into Veterinary indications (Feline Infectious Peritonitis) and Hand-Foot-and-Mouth disease.

Asset Materials

Contact Us for Full Materials